03320.HK
China Resources Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 4.35
+1.75%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 4.29
From 52W high−33.08%
Volume21.81M
Market capHKD 27.33B
P/E (TTM)5.8x
P/S (TTM)0.1x
Div yield5.51%
Key dataSep 18, 2026
Open
HKD 4.29
From 52W high
−33.08%
Volume
21.81M
Market cap
HKD 27.33B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
9.9x
P/E (TTM)
5.8x
RSI (14)
39.2
MomentumView details →
1D Return
+1.75%
YTD Return
−2.25%
Similar companies
Latest newsMore news →
China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.3d agoChina Resources Pharmaceutical's subsidiary China Resources Sanjiu received approval from the National Medical Products Administration to launch mupirocin ointment in mainland China.10d agoChina Resources Pharmaceutical Group Limited advanced its innovative drug pipeline, with a Class 1 antidepressant entering Phase IIb, DC6001 receiving clinical trial approvals in China and the U.S. and FDA Pediatric Rare Disease Designation, and DC7001A filed in China and the U.S.27d ago